The addition of Dyax Inc.'s phage display technology to its portfolio of antibody technologies represents another move by Abgenix Inc. to explore higher throughput options than the use of hybridomas to screen for antibodies with desired characteristics.

ABGX, which is looking to move 100 of its targets through the discovery engine each year, last year announced a $77 million stock acquisition of ImmGenics Inc. (Vancouver, B.C.), which develops technology for rapidly screening antibodies from antibody-producing B cells rather than hybridoma cell lines